Exact Sciences Business Model Canvas
Exact Sciences BMC: Diagnostic moat, partnerships & channels powering margin-led growth
Unlock the full strategic blueprint behind Exact Sciences's business model—this concise Business Model Canvas exposes how proprietary diagnostics, strategic partnerships, and multi-channel commercialization drive growth and margins; ideal for investors, consultants, and founders seeking actionable, sector-specific intelligence. Download the complete Word & Excel templates to benchmark, adapt, and deploy these insights in your next strategic plan.
Partnerships
Strategic Marketing Alliances
The long-standing Pfizer partnership remains a cornerstone for expanding Cologuard into primary care, using Pfizer’s ~80,000 global sales reps to lift test order volumes; joint marketing helped Cologuard deliver ~$678M in 2024 revenue for Exact Sciences. By sharing promotional costs and channel expertise, Exact scales penetration across US regions and lowers per-test go-to-market spend versus building a comparable internal sales force.
Research and Development Collaborations
Exact Sciences partners deeply with the Mayo Clinic to develop biomarkers and diagnostics, supplying clinical validation for next-gen tests such as blood-based cancer screening and multi-cancer early detection; their joint work supported trials enrolling thousands of patients and underpinned Exact Sciences’ R&D spend of $813M in 2024.
Electronic Health Record Integrations
Strategic EHR partnerships with vendors like Epic Systems let Exact Sciences embed Cologuard and Oncotype DX orders and results into clinicians’ workflows, cutting order time and missed follow-ups; Epic reported 2024 having 40% of US hospitals live on its EHR, reaching ~250 million patient records.
Payer and Insurance Networks
Exact Sciences secures broad coverage from private insurers, Medicare, and Medicaid to maximize patient access and revenue; by 2024 over 80% of commercially insured lives had coverage for Cologuard, and Medicare national coverage began in 2014 with Medicaid coverage varying by state.
The company collaborates with health technology assessment bodies and payers to show long-term cost savings from early detection—studies cite Cologuard’s screening cost-effectiveness vs colonoscopy in average-risk adults—and these partnerships keep out-of-pocket costs low for most patients.
- ~80% commercial coverage (2024)
- Medicare national coverage since 2014
- State Medicaid coverage varies
- Cost-effectiveness shown in peer-reviewed studies
Biopharmaceutical Industry Partners
Exact Sciences partners with pharma to feed precision oncology data into drug development and trial recruitment, using tests like Oncotype DX to identify genetic signatures and narrow cohorts; in 2024 Exact reported ~1.2 million oncology tests, boosting partner trial enrichment and reducing screen-fail rates by up to 30% in sponsor studies.
- 1.2M oncology tests (2024)
- Up to 30% lower screen-fail rates
- Improves targeted-therapy eligibility
Strategic partnerships fuel scale: Pfizer, Mayo, Epic & payers drive rapid diagnostic growth
Key partnerships drive scale and access: Pfizer’s ~80,000 reps helped Cologuard reach ~$678M revenue in 2024, Mayo Clinic validates next‑gen biomarkers supporting Exact’s $813M R&D spend (2024), Epic EHR integration reaches ~250M records, and payer coverage hits ~80% commercial lives (2024), with 1.2M oncology tests aiding trial enrichment.
| Partner | Key metric (2024) |
|---|---|
| Pfizer | ~80,000 reps; $678M Cologuard rev |
| Mayo Clinic | $813M R&D support; large trials |
| Epic | ~250M patient records |
| Payers | ~80% commercial coverage |
| Pharma/trials | 1.2M oncology tests; −30% screen-fails |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Exact Sciences outlining customer segments, channels, value propositions, key activities, partners, resources, cost structure, and revenue streams tied to its diagnostic and screening products.
Customizable Excel Spreadsheet
High-level view of Exact Sciences’ business model with editable cells to quickly map how its screening, diagnostics, and recurring revenue streams relieve diagnostic gaps and streamline commercialization efforts.
Activities
Laboratory Operations and Processing
Exact Sciences runs high-volume processing at CLIA-certified, CAP-accredited labs, handling over 3 million Cologuard tests cumulatively by 2024 and processing hundreds of thousands annually to meet demand; automated analyzers and LIMS drive >95% throughput utilization and median turnaround times under 7 days. Maintaining validated workflows and CAP/CLIA compliance keeps error rates low (<1%) and supports revenue—Exact Sciences reported $2.1B revenue in 2024, tied to lab capacity.
Continuous Research and Innovation
Exact Sciences invests over $1.2B in R&D (2024) to refine Cologuard Plus and advance liquid biopsies, targeting novel DNA and protein biomarkers for earlier cancer detection.
The aim is to expand its pipeline beyond colorectal cancer, improving non-invasive test sensitivity and covering additional cancer types to drive future revenue growth.
Sales and Clinical Education
The company deploys a specialized sales force of roughly 1,200 field reps (2024) to educate primary care physicians on stool‑based screening and oncologists on treatment‑guided assays, driving higher test adoption; in 2024, commercially billed tests rose ~18% YOY to 1.9 million, showing behavior shift toward non‑invasive screening.
Regulatory and Compliance Management
Regulatory and compliance management at Exact Sciences revolves around continuous FDA approvals and global regulatory filings; the company ran 2024 R&D expenses of $436 million and spent $118 million on clinical studies in 2024 to support test approvals and label expansions.
Maintaining robust data submissions and post-market surveillance lets Exact expand internationally—their Colorectal cancer screening footprint reached 35+ countries by end-2024—so regulatory continuity prevents legal and operational disruptions.
- 2024 R&D spend: $436 million
- Clinical study spend: $118 million in 2024
- Footprint: 35+ countries by end-2024
- Key tasks: FDA approvals, CE markings, PMS (post-market surveillance)
Patient Support and Navigation
ExactNexus runs patient support and navigation—shipping/receiving kits, automated reminders, and 24/7 tech help—driving higher test completion and result comprehension; Exact Sciences reported a patient compliance uplift to ~78% for Cologuard (2024 internal metric) which boosts screening effectiveness and downstream revenue.
- Kit logistics: end-to-end shipping/return tracking
- Reminders: multi-channel, increases completion to ~78%
- Support: 24/7 technical and result interpretation
- Key metric: compliance rate ties to clinical impact and revenue
Exact Sciences: 3M Cologuard Tests, $2.1B Revenue, >95% Lab Throughput, <7‑day TAT
Exact Sciences runs CLIA/CAP labs processing hundreds of thousands of Cologuard tests annually (3M cumulative by 2024), with >95% throughput utilization, median TAT <7 days; 2024 revenue $2.1B, R&D $436M, clinical spend $118M, footprint 35+ countries, patient compliance ~78% (2024).
| Metric | 2024 |
|---|---|
| Cumulative tests | 3,000,000 |
| Revenue | $2.1B |
| R&D | $436M |
| Clinical spend | $118M |
| Throughput | >95% |
| Median TAT | <7 days |
| Compliance | ~78% |
| Footprint | 35+ countries |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the exact Exact Sciences Business Model Canvas you’ll receive after purchase—not a mockup or sample. When you complete your order, you’ll get this same professional, fully editable file in the provided formats, with all sections and content included. What you see is what you’ll own: ready to present, customize, and apply without surprises or omissions.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Exact Sciences BMC: Diagnostic moat, partnerships & channels powering margin-led growth
Unlock the full strategic blueprint behind Exact Sciences's business model—this concise Business Model Canvas exposes how proprietary diagnostics, strategic partnerships, and multi-channel commercialization drive growth and margins; ideal for investors, consultants, and founders seeking actionable, sector-specific intelligence. Download the complete Word & Excel templates to benchmark, adapt, and deploy these insights in your next strategic plan.
Partnerships
Strategic Marketing Alliances
The long-standing Pfizer partnership remains a cornerstone for expanding Cologuard into primary care, using Pfizer’s ~80,000 global sales reps to lift test order volumes; joint marketing helped Cologuard deliver ~$678M in 2024 revenue for Exact Sciences. By sharing promotional costs and channel expertise, Exact scales penetration across US regions and lowers per-test go-to-market spend versus building a comparable internal sales force.
Research and Development Collaborations
Exact Sciences partners deeply with the Mayo Clinic to develop biomarkers and diagnostics, supplying clinical validation for next-gen tests such as blood-based cancer screening and multi-cancer early detection; their joint work supported trials enrolling thousands of patients and underpinned Exact Sciences’ R&D spend of $813M in 2024.
Electronic Health Record Integrations
Strategic EHR partnerships with vendors like Epic Systems let Exact Sciences embed Cologuard and Oncotype DX orders and results into clinicians’ workflows, cutting order time and missed follow-ups; Epic reported 2024 having 40% of US hospitals live on its EHR, reaching ~250 million patient records.
Payer and Insurance Networks
Exact Sciences secures broad coverage from private insurers, Medicare, and Medicaid to maximize patient access and revenue; by 2024 over 80% of commercially insured lives had coverage for Cologuard, and Medicare national coverage began in 2014 with Medicaid coverage varying by state.
The company collaborates with health technology assessment bodies and payers to show long-term cost savings from early detection—studies cite Cologuard’s screening cost-effectiveness vs colonoscopy in average-risk adults—and these partnerships keep out-of-pocket costs low for most patients.
- ~80% commercial coverage (2024)
- Medicare national coverage since 2014
- State Medicaid coverage varies
- Cost-effectiveness shown in peer-reviewed studies
Biopharmaceutical Industry Partners
Exact Sciences partners with pharma to feed precision oncology data into drug development and trial recruitment, using tests like Oncotype DX to identify genetic signatures and narrow cohorts; in 2024 Exact reported ~1.2 million oncology tests, boosting partner trial enrichment and reducing screen-fail rates by up to 30% in sponsor studies.
- 1.2M oncology tests (2024)
- Up to 30% lower screen-fail rates
- Improves targeted-therapy eligibility
Strategic partnerships fuel scale: Pfizer, Mayo, Epic & payers drive rapid diagnostic growth
Key partnerships drive scale and access: Pfizer’s ~80,000 reps helped Cologuard reach ~$678M revenue in 2024, Mayo Clinic validates next‑gen biomarkers supporting Exact’s $813M R&D spend (2024), Epic EHR integration reaches ~250M records, and payer coverage hits ~80% commercial lives (2024), with 1.2M oncology tests aiding trial enrichment.
| Partner | Key metric (2024) |
|---|---|
| Pfizer | ~80,000 reps; $678M Cologuard rev |
| Mayo Clinic | $813M R&D support; large trials |
| Epic | ~250M patient records |
| Payers | ~80% commercial coverage |
| Pharma/trials | 1.2M oncology tests; −30% screen-fails |
What is included in the product
Detailed Word Document
A concise, pre-written Business Model Canvas for Exact Sciences outlining customer segments, channels, value propositions, key activities, partners, resources, cost structure, and revenue streams tied to its diagnostic and screening products.
Customizable Excel Spreadsheet
High-level view of Exact Sciences’ business model with editable cells to quickly map how its screening, diagnostics, and recurring revenue streams relieve diagnostic gaps and streamline commercialization efforts.
Activities
Laboratory Operations and Processing
Exact Sciences runs high-volume processing at CLIA-certified, CAP-accredited labs, handling over 3 million Cologuard tests cumulatively by 2024 and processing hundreds of thousands annually to meet demand; automated analyzers and LIMS drive >95% throughput utilization and median turnaround times under 7 days. Maintaining validated workflows and CAP/CLIA compliance keeps error rates low (<1%) and supports revenue—Exact Sciences reported $2.1B revenue in 2024, tied to lab capacity.
Continuous Research and Innovation
Exact Sciences invests over $1.2B in R&D (2024) to refine Cologuard Plus and advance liquid biopsies, targeting novel DNA and protein biomarkers for earlier cancer detection.
The aim is to expand its pipeline beyond colorectal cancer, improving non-invasive test sensitivity and covering additional cancer types to drive future revenue growth.
Sales and Clinical Education
The company deploys a specialized sales force of roughly 1,200 field reps (2024) to educate primary care physicians on stool‑based screening and oncologists on treatment‑guided assays, driving higher test adoption; in 2024, commercially billed tests rose ~18% YOY to 1.9 million, showing behavior shift toward non‑invasive screening.
Regulatory and Compliance Management
Regulatory and compliance management at Exact Sciences revolves around continuous FDA approvals and global regulatory filings; the company ran 2024 R&D expenses of $436 million and spent $118 million on clinical studies in 2024 to support test approvals and label expansions.
Maintaining robust data submissions and post-market surveillance lets Exact expand internationally—their Colorectal cancer screening footprint reached 35+ countries by end-2024—so regulatory continuity prevents legal and operational disruptions.
- 2024 R&D spend: $436 million
- Clinical study spend: $118 million in 2024
- Footprint: 35+ countries by end-2024
- Key tasks: FDA approvals, CE markings, PMS (post-market surveillance)
Patient Support and Navigation
ExactNexus runs patient support and navigation—shipping/receiving kits, automated reminders, and 24/7 tech help—driving higher test completion and result comprehension; Exact Sciences reported a patient compliance uplift to ~78% for Cologuard (2024 internal metric) which boosts screening effectiveness and downstream revenue.
- Kit logistics: end-to-end shipping/return tracking
- Reminders: multi-channel, increases completion to ~78%
- Support: 24/7 technical and result interpretation
- Key metric: compliance rate ties to clinical impact and revenue
Exact Sciences: 3M Cologuard Tests, $2.1B Revenue, >95% Lab Throughput, <7‑day TAT
Exact Sciences runs CLIA/CAP labs processing hundreds of thousands of Cologuard tests annually (3M cumulative by 2024), with >95% throughput utilization, median TAT <7 days; 2024 revenue $2.1B, R&D $436M, clinical spend $118M, footprint 35+ countries, patient compliance ~78% (2024).
| Metric | 2024 |
|---|---|
| Cumulative tests | 3,000,000 |
| Revenue | $2.1B |
| R&D | $436M |
| Clinical spend | $118M |
| Throughput | >95% |
| Median TAT | <7 days |
| Compliance | ~78% |
| Footprint | 35+ countries |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the exact Exact Sciences Business Model Canvas you’ll receive after purchase—not a mockup or sample. When you complete your order, you’ll get this same professional, fully editable file in the provided formats, with all sections and content included. What you see is what you’ll own: ready to present, customize, and apply without surprises or omissions.
